---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-015894"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:49:46.338292+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M

## Summary
- Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.
- Net loss of $5.5M ($0.06 per share) improved from $6.7M loss ($0.09) in prior-year period.
- Cash and equivalents $7.3M as of Dec 31, 2025; raised net proceeds of ~$15.1M via December 2025 registered offering.
- LYMPHIR (denileukin diftitox-cxdl) launched for relapsed/refractory Stage I-III cutaneous T-cell lymphoma; patient initiations underway at leading U.S. cancer centers.
- AI-enabled commercial platform deployed; international access advanced through regional distribution partners in Europe and Middle East.

## SEC filing metadata
- accession: 0001213900-26-015894
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/0001213900-26-015894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/ea0276947-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-015894
- JSON: https://secwatch.observer/filing/0001213900-26-015894.json
- Plain text: https://secwatch.observer/filing/0001213900-26-015894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.